Home / Research Tools
Research Tools
| | Corporate Profile: Biovaxys Technology Corp
Publisher: Kaiser Research Online
Author: Copyright 2022 John A. Kaiser
|
| |
| Biovaxys Technology Corp (BIOV-CSE) |
|---|
| Trade Date | Volume | High | Low | Close | Chg | Status |
| April 19, 2024 | 151,400 | $0.09 | $0.08 | $0.08 | $0.00 | Trading |
Issued
92,338,681 |
Price
$0.080 |
Working Capital
($457,815) |
Key People: Jeremy Poirier (CEO), Julia Stone (CFO), |
Diluted
119,331,346 |
Insiders
3.1% |
As of
1/31/2022 |
| Company supplied Corporate Overview - not available |
| The free corporate profile serves as a fast gateway for KRO members via the map cards to resources such as the KRO Profile which includes financial, insider and project details as well as news releases and KRO comments for which headline links are provided below. Links to the company's web site and project web pages are available within this free corporate profile if the company has a multi-user corporate membership (they are always available in full member only KRO Profile). A corporate membership provides the company with complete multiple user access to KRO resources and entitles the company to provide a corporate overview for the subject company's unrestricted corporate profile. |
| Apr 18, 2024 | Provides Bi Weekly MCTO Status Update |
| Apr 10, 2024 | And Spayvac for Wildlife, Inc. Announce Launch of Field Trial for Large Scale Immunocontraception in the Commercial Aquatic Farming Industry |
| Apr 5, 2024 | Provides Bi Weekly MCTO Status Update |
| Apr 3, 2024 | Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMAGE |
| Mar 22, 2024 | Planned private placement |
| Mar 21, 2024 | Provides Bi Weekly MCTO Status Update |
| Mar 8, 2024 | Granted Voluntary Management Cease Trade Order |
| Mar 7, 2024 | Provides Bi Weekly MCTO Status Update |
| Mar 6, 2024 | Granted Voluntary Management Cease Trade Order |
| Mar 5, 2024 | Allowance of DPX Related Patent for Japan and Filing of Additional International Patent Applications |
| Feb 21, 2024 | Annual Financial Statements Update for the Year Ended October 31, 2023 |
| Feb 21, 2024 | Completes the Acquisition of All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc. |
| Feb 12, 2024 | Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc. |
| Feb 12, 2024 | Completion of first tranche of private placement |
| Feb 1, 2024 | Completion of First Tranche of Private Placement |
| Feb 1, 2024 | Completion Of First Tranche Of Private Placement |
| Feb 1, 2024 | Biovaxys Announces Completion Of First Tranche Of Private Placement |
| Jan 29, 2024 | Completed Debt Settlement |
| Jan 8, 2024 | Planned Private Placement and Debt Settlement |
| Dec 22, 2023 | Executes Letter of Intent for Major Immunotherapeutics Technology Acquisition |
| Dec 22, 2023 | BioVaxys and Procare Health Agree to Termination of USA Distribution Agreement for Papilocare |
| Dec 13, 2023 | In Non Binding Discussions for Major Immunotherapeutics Technology Acquisition |
| Aug 30, 2023 | BioVaxys and The Ohio State University Extend Research Collaboration |
| Jun 30, 2023 | Management Change |
| Jun 14, 2023 | Sale of TAET Software Co |
| Jun 14, 2023 | Sale of Taet Software CO |
| Jun 7, 2023 | AGM Results |
| Apr 19, 2023 | Details shareholder value with retention of Maxim to achieve US stock exchange listing |
| Apr 17, 2023 | Retains Maxim Group as financial advisor and investment banker |
| Apr 17, 2023 | Retains Maxim Group As Financial Advisor And Investment Banker |
| Apr 12, 2023 | Appointment of CFO and Board Changes |
| Mar 17, 2023 | Acquires TAETSoftware to Utilize Trial Adverse Events Tracker Platform |
| Mar 16, 2023 | Acquires clinical study management company and completes private placement |
| Dec 19, 2022 | and Procare Health Execute US Distribution Agreement for Papilocare Gel and Oral Immunocaps |
| Dec 5, 2022 | Co Founder, President and Chief Operating Officer Kenneth Kovan to Present at MedInvest Oncology Investor Conference |
| Dec 1, 2022 | Successful Test Run Production of its Bi Haptenized Ovarian Cancer Vaccine |
| Nov 29, 2022 | Closes First Tranche of Non brokered Private Placement |
| Nov 29, 2022 | Closes first tranche of non brokered private placement |
| Nov 16, 2022 | Sarbecovirus Vaccine Interim Data Excellent Emerging Safety & Tolerability Profile with BVX 1021 |
| Nov 10, 2022 | Completed Private Placement and Debt Settlement |
| Oct 27, 2022 | Debt Settlement |
| Oct 14, 2022 | Completed debt settlement |
| Oct 6, 2022 | Debt Settlement |
| Oct 6, 2022 | Executes Binding Term Sheet for the US Marketing & Distribution For Papilocare Gel and Oral Immunocaps |
| Sep 28, 2022 | Further Expands Vaccines Intellectual Property Portfolio |
| Sep 20, 2022 | Closes Final Tranche of Non brokered Private Placement |
| Sep 8, 2022 | New Chief Financial Officer |
| Sep 6, 2022 | Completed synthesis of its Pan Sarbecovirus Vaccine Candidate and Launch of in Vivo Animal Study |
| Aug 26, 2022 | Closes first tranche of non brokered private placement |
| Aug 9, 2022 | Warrant Extension |
| Aug 4, 2022 | Non Brokered Private Placement |
| Aug 2, 2022 | Completed Debt Settlement |
| Jul 5, 2022 | Proposed Debt Settlement |
| Jun 15, 2022 | Clinical Study Collaborator HCL Sends First Surgically Excised Ovarian Cancer Tumors to BioVaxys for BVX 0918 Vaccine Process Development |
| Jun 8, 2022 | Bio Manufacturing Partner BioElpida Completes Next Phase of BVX 0918 GMP Production for EU Clinical Study |
| Jun 3, 2022 | and The Ohio State University Progress Pan Sarbecovirus Vaccine Research Program |
| May 18, 2022 | Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement |
| May 2, 2022 | International Patent Application Filed for Cervical Cancer Vaccine |
| Apr 29, 2022 | Appointment To Board Of Directors |
| Apr 25, 2022 | Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX 0918 Bioproduction |
| Mar 30, 2022 | Expands Cancer Vaccine Platform |
| Mar 24, 2022 | Race to Develop Universal 'Variant Proof' Covid Vaccine Involves Several Players |
| Mar 17, 2022 | Bioproduction of BVX 1021 for its Pan Sarbecovirus Program in Collaboration with The Ohio State University |
| Feb 28, 2022 | Closes Final Tranche of Non brokered Private Placement |
| Feb 16, 2022 | Complete Inhibition of ACE 2 Binding Activity of Hapten modified SARS CoV 2 Protein |
| Feb 10, 2022 | Closes First Tranche Of Non brokered Private Placement |
| Feb 8, 2022 | Non brokered Private Placement |
| Dec 7, 2021 | Biotech Sector's Response to Omicron Panic Should be Swift and Effective |
| Dec 7, 2021 | Major Research Collaboration With The Ohio State University To Develop Broadly Reactive Pan Sarbecovirus Vaccine |
| Nov 18, 2021 | BioVaxys Chief Medical Officer David Berd, MD, Invited by Editorial Board of Therapeutic Advances in Vaccines and Immunotherapy to Submit a Review Article on Haptenized Protein Vaccine Platform |
| Nov 17, 2021 | Co Founder and Chief Medical Officer David Berd, MD, to Present At World Vaccine & Immunotherapy Congress West Coast 2021 |
| Nov 9, 2021 | CoviDTH Demonstrates Safety and Tolerability in Broad Ranging In Vivo Clinical Pathology, Immunology, and Histopathology Evaluation, Supporting Planned Clinical Development of CoviDTH |
| Oct 28, 2021 | Further Expands Intellectual Property Portfolio in Global Markets |
| Oct 20, 2021 | Files US Patent Application for Pan Sarbecovirus Vaccine |
| Oct 8, 2021 | BVX 0320 Poster Presentation at ISIRV WHO Virtual Conference |
| Sep 28, 2021 | Begins Toxicity Study Ahead of CoviDTH IND Submission |
| Sep 23, 2021 | Prepares for Groundbreaking Study on reduced ACE2 binding capabilities of Hapten modified SARS CoV 2 proteins |
| Sep 20, 2021 | ENGAGES life sciENCES Public relations and market communications firm 6 degrees |
| Sep 17, 2021 | Cancer Vaccine Manufacturing Partner Bio Elpida Reaches Bioproduction Milestone |
| Sep 14, 2021 | Bioproduction Partner WuXi Biologics Completes Synthesis Of Recombinant SARS CoV 2 s proteins for BVX 0320 and CoviDTH Programs |
| Sep 7, 2021 | Further Study in humans shows that the DTH response, the basis for CoviDTH, is highly durable and persists for at least one year after COVID 19 exposure or vaccine administration |
| Aug 3, 2021 | Clinical Trial Affirms CoviDTH Diagnostic Approach to Screen for T Cell mediated Immune Response to SARS CoV 2 is Safe and Effective in Humans |
| Jul 29, 2021 | Closes Final Tranche Of Non Brokered Private Placement |
| Jul 22, 2021 | IIROC Trade Resumption BIOV |
| Jul 22, 2021 | FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH |
| Jul 21, 2021 | IIROC Trading Halt BIOV |
| Jul 15, 2021 | Closes First Tranche Of Non brokered Private Placement |
| Jun 29, 2021 | Non Brokered Private Placement |
| Jun 15, 2021 | Receives Positive FDA Response For Pre IND Review For CoviDTH Clinical Development |
| Jun 1, 2021 | BioVaxys And Bioproduction Partner Bio Elpida Begin Construction Of GMP Facility To Produce Clinical Supply For Planned Ovarian Cancer Vaccine Study |
| May 24, 2021 | Strengthens Internal Expertise With Appointment Of Scientific Advisor For Ovarian Cancer Vaccine Clinical Program And Papilocare Marketing |
| May 20, 2021 | Appointment of Policy Advisor |
| May 19, 2021 | Uplisting To The OCTQB Venture Market |
| May 3, 2021 | And BioElpida Sign Definitive Exclusive Agreement To Begin Ovarian Cancer Vaccine Bioproduction |
| May 3, 2021 | BioVaxys And BioElpida Sign Definitive Exclusive Agreement To Begin Ovarian Cancer Vaccine Bioproduction |
| Apr 29, 2021 | Broadens Intellectual Property Portfolio Commercial Trademark Application Filed for CoviDTH(r) Diagnostic |
| Apr 21, 2021 | Assigned "BVAXF" By Finra As New US OTC Trading Symbol |
| Apr 20, 2021 | Biovaxys And The World Ovarian Cancer Coalition Join Forces For May 8th, World Ovarian Cancer Day |
| Apr 20, 2021 | The World Ovarian Cancer Coalition Join Forces For May 8th, World Ovarian Cancer Day |
| Apr 14, 2021 | Final Clinical trial results of HPV product from EU partner ProCare Health Iberia published by American Society for Colposcopy and Cervical Pathology |
| Mar 31, 2021 | Files FDA pre IND meeting request and briefing package for COVID T |
| Mar 24, 2021 | Expands Intellectual Property Portfolio |
| Mar 18, 2021 | BioVaxys Enters Agreement With Inotiv To Conduct Preclinical Toxicity Studies For Its Covid T(TM) Immunodiagnostic Program |
| Mar 18, 2021 | Enters Agreement With Inotiv To Conduct Preclinical Toxicity Studies For Its Covid T(TM) Immunodiagnostic Program |
| Mar 15, 2021 | Enters Major Bioproduction Agreement With Wuxi Biologics (Hong Kong) Ltd. To Synthesize Proteins For Its SARS CoV 2 Vaccine And COVID T(TM) Immunodiagnostic Programs |
| Mar 1, 2021 | Expanding Technology Platform To Address Emerging SARS CoV 2 Variants |
| Feb 22, 2021 | Appointment To Its Scientific Advisory Board |
| Feb 18, 2021 | and BioElpida Sign Term Sheet for Clinical Grade BVX 0918A Bio Production |
| Feb 16, 2021 | Broadening Of Share Liquidity With DTCC Full Service Eligibility |
| Feb 12, 2021 | Appointment of Corporate Advisor |
| Feb 10, 2021 | BioVaxys and Procare Health Announce Broad Co Development, Joint Commercialization and Marketing Collaboration for Cancer and Viral Vaccines |
| Feb 8, 2021 | Director Change |
| Feb 5, 2021 | Closing of Financing |
| Feb 2, 2021 | SARS CoV 2 Vaccine Candidate BVX 0320 Stimulates Neutralizing Antibodies To Live COVID 19 Virus |
| Feb 1, 2021 | Investment By Strategic Investor |
| Jan 28, 2021 | Covid T(TM) Clinical Development Program Initiated Regulatory Advisory Group Engaged |
| Jan 25, 2021 | Initiation of Cancer Vaccine EU Clinical Program, Completion of BVX 0320 Preclinical Program |
| Dec 21, 2020 | Vaccine Platform Stimulates Robust T cell Response Against Viral Antigens |
| Dec 10, 2020 | Form 211 Clearance For OTC Trading in the USA |
| Nov 30, 2020 | Provides Viral Vaccine Platform Program Update |
| Nov 11, 2020 | 96.4 Percent Positive Antibody Immune Response Results from an In Vivo Murine Model Study of Its SARS CoV 2 Vaccine |
| Nov 9, 2020 | Engages Advisor for Strategic Business Development |
| Nov 2, 2020 | Files Patent Application for Novel COVID 19 Diagnostic for T Cell Immunity |
| Oct 26, 2020 | BioVaxys and The Ohio State University Enter into SARS CoV 2 Research Collaboration to Study New Vaccine |
| Oct 21, 2020 | Appointment of New Director |
| Oct 14, 2020 | Interim Results from Preclincal Study of Its SARS CoV 2 Vaccine |
| Oct 6, 2020 | Closing of Acquisition of BioVaxys Inc. |
| Oct 5, 2020 | CSE Bulletin: Fundamental Change Lions Bay Mining Corp./BioVaxys Technology Corp. |
| Oct 5, 2020 | CSE Bulletin: Fundamental Change Lions Bay Mining Corp./BioVaxys Technology Corp. |
| Sep 14, 2020 | Removed from BCSC Delinquent Filer List - 2020/08/14 OT Filings |
| Sep 4, 2020 | Closing of Final Tranche of Non Brokered Private Placement and Provides Update on Completion of Production and Start of Dosing in BioVaxys' Preclincal Study Of SARS CoV 2 Vaccine |
| Sep 3, 2020 | Filing of Technical Report |
| Aug 26, 2020 | Closing of First Tranche of Non brokered Private Placement Update on Biovaxys Acquisition |
| Jul 6, 2020 | Change of Officer |
| Jun 23, 2020 | Execution of Secured Lending Facility with BioVaxys Inc. and Production of Vaccine Candidate for Preclinical Study |
| Jun 4, 2020 | Definitive Agreement for BioVaxys Acquisition and Concurrent Financing |
| May 14, 2020 | Update on Acquisition Target BioVaxys Initiating A SARS CoV 2 Vaccine Study and Definitive Agreement |
| Apr 28, 2020 | CSE Bulletin: Split Lions Bay Mining Corp. (LBM) |
| Apr 27, 2020 | Confirms Forward Split and Record Date |
| Apr 20, 2020 | Non Binding LOI to Acquire BioVaxys LLC, a Clinical Stage Biopharma Company Developing Immunotherapeutic Vaccines for Life threatening Viral Infections and Cancers |
| Apr 17, 2020 | Proposed Stock Split |
| Oct 17, 2019 | Improved Cash Position from Sale of Lions Bay Shares |
| Apr 2, 2019 | Return of Hy and Jay Property |
| Nov 22, 2018 | Listing on CSE and Completion of Private Placement |
|
| |
| | You can return to the Top of this page
|
|
